New study tracks Long-Term safety of danicopan combo for rare blood disorder
NCT ID NCT07413250
First seen Feb 24, 2026 · Last updated May 05, 2026 · Updated 9 times
Summary
This study looks at the long-term safety of adding danicopan to standard treatments (ravulizumab or eculizumab) for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Researchers will analyze data from 50 adults already enrolled in a PNH registry to track side effects, infections, and other health issues. The goal is to better understand the risks of this combination therapy over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Boston, Massachusetts, 02210, United States
Conditions
Explore the condition pages connected to this study.